EQT Fund Management’s AgomAb Therapeutics NV AGMB Stock Holding History
Bought
Maintained
Sold
Other funds holding AGMB
SL
EQT Fund Management's AGMB Position: Q3 2026 in Review
EQT Fund Management held its AgomAb Therapeutics NV (AGMB) position steady in Q3 2026 at 5,141,992 shares worth $57.1M. The position accounts for 6.02% of the portfolio, ranked #4.
EQT Fund Management first reported a position in AGMB in Q1 2026 and has held it in 3 quarters since. The position peaked at $66.7M in Q2 2026. 25 funds tracked by Wall St. Rank hold AGMB as of Q3 2026.
- EQT Fund Management held 5,141,992 shares of AgomAb Therapeutics NV worth $57.1M as of Q3 2026.
- EQT Fund Management left its AgomAb Therapeutics NV share count unchanged in Q3 2026.
- AgomAb Therapeutics NV made up 6.02% of EQT Fund Management's portfolio in Q3 2026, its #4 holding.
- EQT Fund Management first reported a position in AgomAb Therapeutics NV in Q1 2026 and has held it in 3 quarters since.
- EQT Fund Management's AgomAb Therapeutics NV position peaked at $66.7M in Q2 2026.
- 25 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q3 2026.
Based on EQT Fund Management's 13F filing for Q3 2026, filed 12 Nov 2026.